309938-27-0

Usage

Uses

Used in Pharmaceutical Industry:
[1-(2-fluorobenzyl)-1H-benzimidazol-2-yl]methanol is used as a chemical compound for its potential pharmaceutical and medicinal applications. Its structural features and functional groups make it a promising candidate for the development of drugs with various biological activities.
Used in Antimicrobial Applications:
[1-(2-fluorobenzyl)-1H-benzimidazol-2-yl]methanol is used as an antimicrobial agent for its potential to exhibit biological activities against various microorganisms.
Used in Antiviral Applications:
[1-(2-fluorobenzyl)-1H-benzimidazol-2-yl]methanol is used as an antiviral agent for its potential to inhibit viral replication and infection.
Used in Anticancer Applications:
[1-(2-fluorobenzyl)-1H-benzimidazol-2-yl]methanol is used as an anticancer agent for its potential to exhibit biological activities against cancer cells.
Used in Drug Development:
[1-(2-fluorobenzyl)-1H-benzimidazol-2-yl]methanol is used as a compound in drug development for its potential to be incorporated into new drugs with various therapeutic applications.

Upstream product

• 4856-97-7 2-(Hydroxymethyl)benzimidazole 
• 95-54-5 1,2-diamino-benzene 
• 446-48-0 o-fluorobenzyl bromide 

Relevant academic research and scientific papers

Design, synthesis and anti-tumor activity of novel benzimidazole-chalcone hybrids as non-intercalative topoisomerase II catalytic inhibitors

Chemical diversification of type II topoisomerase (Topo II) inhibitors remains indispensable to extend their anti-tumor therapeutic values which are limited by their side effects. Herein, we designed and synthesized a novel series of benzimidazole-chalcone hybrids (BCHs). These BCHs showed good inhibitory effect in the Topo II mediated DNA relaxation assay and anti-proliferative effect in 4 tumor cell lines. 4d and 4n were the most potent, with IC50values less than 5 μM, superior to etoposide. Mechanistic studies indicated that the BCHs functioned as non-intercalative Topo II catalytic inhibitors. Moreover, 4d and 4n demonstrated versatile properties against tumors, including inhibition on the colony formation and cell migration, and promotion of apoptosis of A549 cells. The structure-activity relationship and molecular docking analysis suggested possible contribution of the chalcone motif to the Topo II inhibitory and anti-proliferative potency. These results indicated that 4d and 4n could be promising lead compounds for further anti-tumor drug research.

Discovery of benzimidazole derivatives as potent and selective aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors with glucose consumption improving activity

Aldehyde dehydrogenase 1A1 (ALDH1A1) plays vital physiological and toxicological functions in many areas, such as CNS, inflammation, metabolic disorders, and cancers. Overexpression of ALDH1A1 has been disclosed to play an important role in obesity, diabetes and other diseases, indicating the potential need for the identification and development of small molecule ALDH1A1 inhibitors. Herein, a series of benzimidazole derivatives was designed, synthesized and evaluated. Among them, compounds 21, 27, 29, 61 and 65 exhibited excellent inhibitory activity against ALDH1A1 with IC50 values in the low micromolar range and high selectivity over ALDH1A2, ALDH1A3, ALDH2 and ALDH3A1. Moreover, an in vitro study demonstrated that all five compounds effectively improved glucose consumption in HepG2 cells, of which, 61 and 65 at 10 μM produced nearly equal glucose consumption with positive control Metformin (Met) at 1 mM. Furthermore, 61 and 65 showed desirable metabolic stability in human liver microsomes. All these results suggest that 61 and 65 are suitable for further studies.

Benzimidazole chalcone derivative, and preparation method and application thereof

The invention belongs to the technical field of drug synthesis, and especially relates to a benzimidazole chalcone derivative, and a preparation method and an application thereof. The structural formula of the benzimidazole chalcone derivative is represented by formula (I); and in the formula (I), R1 is fluorine or a methyl group, and R2 is selected from a nitro group, a cyano group, fluorine, chlorine, bromine, a methyl group, a methoxy group, a dimethoxy group, a trimethoxy group, an ethyl group and an isopropyl group. Results of studies show that the benzimidazole chalcone derivative of thepresent invention can target DNA topoisomerase II, can effectively inhibit the activity of human DNA topoisomerase II (TopoII), and can be used for preparing antitumor drugs with topoisomerase II asa target. The benzimidazole chalcone derivative of the present invention has a strong inhibitory effect on the proliferation of a plurality of tumor cells, and can be used for preparing anticancer drugs.

Design, synthesis and biological evaluation of benzimidazole-rhodanine conjugates as potent topoisomerase II inhibitors

In this study, a series of benzimidazole-rhodanine conjugates were designed, synthesized and investigated for their topoisomerase II (Topo II) inhibitory and cytotoxic activities. The results from Topo II-mediated pBR322 DNA relaxation and cleavage assays showed that the synthesized compounds might act as Topo II catalytic inhibitors. Certain compounds displayed potent Topo II inhibition at 10 μM. The cytotoxic activities of these compounds against HeLa, A549, Raji, PC-3, MDA-MB-201, and HL-60 cancer cell lines were evaluated. The results indicated that these compounds exhibited strong antiproliferative activity. A good relationship was observed between the Topo II inhibitory potency and the cytotoxicity of these compounds. The structure-activity relationship revealed that the electronic effects, the phenyl group, and the rhodanine moiety were particularly important for the Topo II inhibitory potency and cytotoxicity.